Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegAsp vs IGlar + IAsp in T2D Intensification
NCT02906917Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c at 26 weeks. Started Sep 2016; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02906917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906917.